Company Profile

Industry Sector: Biotech/Pharmaceutical

Company Overview: Antigen Discovery Inc. (ADI, formerly Immport Therapeutics)’s unique technology platform alleviates the major bottleneck that currently limits the transformation of genomic information into next generation medical advancements. This technology rapidly identifies novel biomarkers for new diagnostic tests, vaccine targets, and therapeutic proteins directed towards infectious organisms and clinical disease states such as autoimmunity and cancer. ADI’s powerful technology is also ideal for both preclinical and human clinical trial applications such as enrollment screening and endpoint assessment.

Target Market(s): Health Care centers, reference labs, hospitals worldwide

Management

Leadership:
Xiaowu Liang, President and CEO
Philip L. Felgner, Chairman of the Board
Keith Hoffman, Business Development

Scientific Advisory Board:
Luis de la Maza, Ph.D., MD: Head of Infectious Disease Laboratory at UCI Medical Center
Tony James, Ph.D.: Distinguished Professor of Molecular Genetics at UC Irvine, National Academy Member
Philip L. Felgner, Ph.D.: Adjunct Professor of Infectious Disease at UC Irvine
W. John Morrow, Ph.D.: Distinguished immunologist and autoimmune disease expert, Director of New Technology Acquisition at InBios

Key Value Drivers

Technology*: ADI technology comprises a process for high speed comprehensive surveying of mammalian immune responses in a high throughput format. This technology rapidly identifies novel biomarkers for new diagnostic tests, vaccine targets, and therapeutic proteins directed towards infectious organisms and clinical disease states such as autoimmunity and cancer. ADI’s powerful technology is also ideal for both preclinical and human clinical trial applications such as enrollment screening and endpoint assessment.

Competitive Advantage: Speed: ADI’s technology is the fastest path to build a product candidate pipeline. At least an order of magnitude faster than conventional approaches, e.g. screening of the entire target proteome can be completed within weeks. Proven success rate: To date >95% of predicted open reading frames have been successfully expressed and printed onto high density proteome chips. No pre-screening or selection of sequences is required. Clinical sample volume size: ADI’s proteomic assays are typically conducted with only 1-10 microliters of blood or sera.

Plan & Strategy: Seeking strategic corporate partners
*Technology funded by the NIAID and being commercialized under the NIH-CAP

Product Pipeline

Serodiagnostic Product Development Pipeline

Basic Research → Prototype Design / Discovery → Preclinical Development → Clinical Development → FDA Filing / Approval & Launch Preparation

- Lupus
- Pancreatic Tumor
- Rheum. Arthritis
- Malaria Flavivirus Panel
- HPV
- HSV
- Tularemia
- Brucellosis
- Lyme Disease
- Tuberculosis
- Poxvirus
- Q4 2009